Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

Bibliography

• Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171-91
   PubMed Web of Science ®Google Scholar
• Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011;2011:222-30
   PubMed Web of Science ®Google Scholar
• Ostojic A, Vrhovac R, Verstovsek S. Ruxolitnib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 2012;8:95-103
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-8
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
   PubMed Web of Science ®Google Scholar
• Tefferi A, Huang J, Schwager S, Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007;109:2083-8
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8
   PubMed Web of Science ®Google Scholar
• JAKAVI® the first medication to receive Health Canada approval to treat patients with myelofibrosis [News release]. Canadian Newswire Web site. Available from: http://www.newswire.ca/en/story/1003655/-pr-jakavi-the-first-medication-to-receive-health-canada-approval-to-treat-patients-with-myelofibrosis 2012. [Accessed 28 August 2012]
   Google Scholar
• Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis [News release]. Novartis Web site. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1636508.shtml 2012. [Accessed 28 August 2012]
   Google Scholar
• Tefferi A, Vaidya R, Caramazza D, Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-63
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127-40
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib J, Jamieson C, SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood 2011;118:abstract 3838
   Google Scholar
• Komrokji RS, Wadleigh M, Seymour JF, Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood 2011;118:abstract 282
   Web of Science ®Google Scholar
• Pardanani A, Gotlib J, Gupta V, An expanded multicenter phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. Blood 2011;118:abstract 3849
   Google Scholar
• Begna KH, Pardanani A, Mesa R, Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012;87:66-8
   PubMed Web of Science ®Google Scholar
• JAKAFI® (ruxolitinib) prescribing information. Incyte Corp; Wilmington, DE: 2011
   Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, McGee RF, The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 2011;51:1644-54
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
   PubMed Web of Science ®Google Scholar
• Shilling AD, Nedza FM, Emm T, Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 2010;38:2023-31
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, Emm T, The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 2012;52:809-18
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
   PubMed Web of Science ®Google Scholar
• Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455-7
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barosi G, Mesa RA, International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Estrov Z, Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202-9
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I. Blood 2011;118:abstract 278
   Google Scholar
• Harrison C, Kiladjian JJ, Gisslinger H, Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study. Blood 2011;118:abstract 279
   Google Scholar
• Mesa R, Gotlib J, Gupta V, Associations between improvements in myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: a randomized, double-blind, phase III trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF. Blood 2011;118:abstract 3842
   Google Scholar
• Harrison CN, Kiladjian JJ, Al-Ali HK, Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitninib versus best available therapy. Blood 2011;118:abstract 795
   Google Scholar
• Talpaz M, Hamburg SI, Jamieson K, Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50 – 100 × 109/L. J Clin Oncol 2012;30(15 Suppl):abstract 6630
   Google Scholar
• Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; published online 14 June 2012; doi: 10.1182/blood-2012-05-399048
   Google Scholar